ACADIA Pharmaceuticals Analyst Initiates Coverage with Bullish Outlook
ByAinvest
Tuesday, Oct 21, 2025 8:41 am ET1min read
ACAD--
Citigroup analyst Yigal Nochomovitz initiated coverage on ACADIA Pharmaceuticals with a Buy rating and a price target of $33. Oppenheimer analyst Jay Olson initiated coverage on iBio with an Outperform rating and a price target of $5. Johnson Rice analyst Martin Malloy initiated coverage on Hyliion Holdings with a Buy rating and a price target of $5. Keybanc analyst Justin Patterson initiated coverage on Hims & Hers Health with a Sector Weight rating. Guggenheim analyst Jonathan Lee initiated coverage on MARA Holdings with a Neutral rating.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet